pembrolizumab sold brand name keytruda humanized antibody used cancer immunotherapy treats melanoma lung cancer head neck cancer hodgkin lymphoma stomach cancer cervical cancer certain types breast given slow injection common side effects include fatigue musculoskeletal pain decreased appetite itchy skin pruritus diarrhea nausea rash fever pyrexia cough difficulty breathing dyspnea constipation pain abdominal isotype antibody blocks protective mechanism cancer cells thereby allows immune system destroy targets programmed cell death protein receptor pembrolizumab approved medical use united states world health organizations list essential pembrolizumab used via intravenous infusion treat inoperable metastatic melanoma metastatic nonsmall cell lung cancer nsclc certain situations firstline treatment metastatic bladder cancer patients receive cisplatinbased chemotherapy high levels secondline treatment head neck squamous cell carcinoma hnscc platinumbased chemotherapy treatment adult pediatric patients refractory classic hodgkins lymphoma chl recurrent locally advanced metastatic esophageal squamous cell nsclc pembrolizumab used combination chemotherapy receptor ligand levels firstline treatment cancer expresses cancer mutations egfr alk chemotherapy already administered pembrolizumab used secondline treatment cancer egfr alk mutations agents targeting mutations used assessment expression must conducted validated approved companion us food drug administration fda approved pembrolizumab unresectable metastatic solid tumor certain genetic anomalies mismatch repair deficiency microsatellite first time fda approved cancer drug based tumor genetics rather tissue type tumor sitemedical citation needed therefore pembrolizumab socalled tissueagnostic european union pembrolizumab indicated june us fda approved new indication pembrolizumab firstline treatment people unresectable metastatic microsatellite instabilityhigh mismatch repair deficient dmmr colorectal approval marks first immunotherapy approved population us firstline treatment administered people without also giving march us fda approved pembrolizumab combination platinum fluoropyrimidinebased chemotherapy treat metastatic locally advanced esophageal gastroesophageal gej tumors epicenter centimeters gastroesophageal junction carcinoma people candidates surgical resection definitive efficacy evaluated multicenter randomized placebocontrolled trial enrolled participants metastatic locally advanced esophageal gastroesophageal junction carcinoma candidates surgical resection definitive may us fda approved pembrolizumab combination trastuzumab fluoropyrimidine platinumcontaining chemotherapy firstline treatment people locally advanced unresectable metastatic positive gastric gastroesophageal junction gej approval based prespecified interim analysis first participants ongoing trial multicenter randomized trial people advanced gastric gastroesophageal junction gej adenocarcinoma previously received systemic therapy metastatic july us fda approved pembrolizumab highrisk earlystage triplenegative breast cancer tnbc combination chemotherapy neoadjuvant treatment continued single agent adjuvant treatment fda also granted regular approval pembrolizumab combination chemotherapy people locally recurrent unresectable metastatic tnbc whose tumors express combined positive score cps determined fdaapproved november us fda approved pembrolizumab adjuvant treatment people twelve years age older stage iib iic melanoma following complete november us fda approved pembrolizumab adjuvant treatment renal cell carcinoma people intermediatehigh high risk recurrence following approval based multicenter randomized doubleblind placebocontrolled trial patients intermediatehigh high risk recurrence rcc evidence march us fda approved pembrolizumab treatment advanced endometrial january us fda approved pembrolizumab adjuvant treatment following resection platinumbased chemotherapy stage ib cm ii iiia nonsmall cell lung october us fda approved pembrolizumab used gemcitabine cisplatin locally advanced unresectable metastatic biliary tract person taking corticosteroids immunosuppressants drugs stopped starting pembrolizumab may interfere pembrolizumab may used pembrolizumab started deal immunerelated adverse women childbearing age use contraception taking pembrolizumab administered pregnant women animal studies shown reduce tolerance fetus increasing risk miscarriage known whether pembrolizumab present breast drug tested people active infections including hiv hepatitis b hepatitis c infection kidney liver disease active central nervous system cns metastases active systemic autoimmune disease interstitial lung disease prior pneumonia people history severe reaction another monoclonal update people severe infusionrelated reactions pembrolizumab also severe immunerelated adverse effects including lung inflammation including fatal cases inflammation endocrine organs caused inflammation pituitary gland thyroid causing hypothyroidism hyperthyroidism different people pancreatitis caused type diabetes diabetic ketoacidosis people go lifelong hormone therapy result eg insulin therapy thyroid hormones people also colon inflammation liver inflammation kidney inflammation due common adverse reactions fatigue rash itchiness pruritus diarrhea nausea joint pain arthralgia adverse effects occurring people taking pembrolizumab included anemia decreased appetite headache dizziness distortion sense taste dry eye high blood pressure abdominal pain constipation dry mouth severe skin reactions vitiligo various kinds acne dry skin eczema muscle pain pain limb arthritis weakness edema fever chills myasthenia gravis flulike pembrolizumab therapeutic antibody binds blocks located lymphocytes receptor generally responsible preventing immune system attacking bodys tissues socalled immune normally receptor activated tcells binds ligands present normal cells body deactivating potential cellmediated immune response many cancers make proteins also bind receptor thus shutting ability body kill pembrolizumab works inhibiting lymphocytes receptors blocking ligands would deactivate prevent immune responsemedical citation needed allows immune system target destroy cancer also blocks key mechanism preventing immune system attacking body checkpoint inhibitor function pembrolizumab thus immunedysfunction side effects tumors often mutations cause impaired dna mismatch repair turn often results microsatellite instability allowing tumor generate numerous mutant proteins could serve tumor antigens triggering immune response tumor preventing selfcheckpoint system blocking pembrolizumab appears facilitate clearance tumor immune system since pembrolizumab cleared circulation nonspecific catabolism metabolic drug interactions expected studies done routes systemic clearance rate lday terminal halflife pembrolizumab immunoglobulin variable region human receptor humanized mouse monoclonal heavy chain disulfide humanized mouse monoclonal Îº light chain dimer recombinantly manufactured chinese hamster ovary cho pembrolizumab invented scientists organon worked medical research council technology became lifearc starting humanize antibody scheringplough acquired organon merck co acquired scheringplough two years inventors gregory carven hans van eenennaam gradus dulos recognized inventors year intellectual property owners education foundation development program pembrolizumab seen high priority organon low schering later merck early merck terminated development began preparing outlicense later scientists bristol myers squibb published paper new england journal medicine showing checkpoint inhibitor ipilimumab yervoy shown strong promise treating metastatic second bristol myers squibb checkpoint inhibitor nivolumab opdivo also merck time little commitment expertise either oncology immunotherapy understood opportunity reacted strongly reactivating program filing ind end one example martin huber one senior people merck strong experience lung cancer drug development promoted senior management longer involved product development stepped role lead clinical development pembrolizumab lung scientists company argued developing companion diagnostic limiting testing drug patients biomarkers showing likely respond received agreement management people including shareholders analysts criticized decision limited potential market size drug others argued increased chances proving drug would work would make clinical trials faster trials would need fewer patients likelihood greater effect size moving quickly reducing risk failure essential catching bristolmyers squibb approximate five year lead phase study started early eric rubin running melanoma trial argued able win expansion trial reached around people largest phase study ever run oncology patients roughly divided melanoma lung merck quietly applied breakthrough therapy designation drug regulatory pathway new time well understood one advantages us fda holds frequent meetings drug developers reducing risk developers making mistakes misunderstandings arising differences regulators expectations developers want mercks first use designation reduction regulatory risk one reasons management willing put company resources united states adopted name usan name changed lambrolizumab year clinical trial results advanced melanoma published new england journal part large phase september us food drug administration fda approved pembrolizumab fast track development approved use following treatment ipilimumab treatment ipilimumab braf inhibitor advanced melanoma patients carry braf targeting drugs market pembrolizumab nivolumab clinical developments class drugs receiving coverage new york april merck applied approval market drug japan signed agreement taiho pharmaceutical copromote july pembrolizumab received marketing approval european october us fda approved pembrolizumab treatment metastatic nonsmall cell lung cancer nsclc people whose tumors express failed treatment chemotherapeutic july us fda accepted priority review application recurrent metastatic head neck squamous cell carcinoma hnscc platinumbased granted accelerated approval pembrolizumab treatment patients recurrent metastatic hnscc regardless staining following progression platinumbased chemotherapy based objective response rates orr phase ib study august may pembrolizumab received accelerated approval us fda use unresectable metastatic solid tumor dna mismatch repair deficiencies microsatellite instabilityhigh state case colon cancer tumors progressed following approval marked first instance fda approved marketing drug based presence genetic mutation limitation site cancer kind tissue approval based clinical trial patients microsatellite instabilityhigh mismatch repair deficient cancers enrolled one five singlearm trials ninety patients colorectal cancer patients one cancer types objective response rate patients response rates similar across cancer types including colorectal cancer across tumor types notably complete responses remainder partial responses responses lasted least six months clinical trial fairly small merck obligated conduct postmarketing studies ensure results pembrolizumab granted orphan drug designation sclc october june us fda approved pembrolizumab use advanced cervical cancer positive treatment adult pediatric patients refractory primary mediastinal large bcell lymphoma pmbcl relapsed two prior lines august us fda updated prescribing information pembrolizumab require use fdaapproved companion diagnostic test determine levels tumor tissue patients locally advanced metastatic urothelial cancer august fda approved dako ihc pharmdx assay dako north america inc companion diagnostic select patients locally advanced metastatic urothelial carcinoma cisplatinineligible treatment assay determines expression using combined positive score cps assessing staining tumor immune august pembrolizumab indicated treatment locally advanced metastatic urothelial carcinoma eligible cisplatincontaining chemotherapy whose tumors express combined positive score cps determined fdaapproved test patients eligible platinumcontaining chemotherapy regardless november us fda granted accelerated approval pembrolizumab hepatocellular carcinoma hcc previously treated february us fda approved pembrolizumab adjuvant treatment patients melanoma involvement lymph nodes following complete fda granted application orphan drug june us fda granted accelerated approval pembrolizumab metastatic small cell lung cancer sclc disease progression platinumbased chemotherapy least one prior line fda approved pembrolizumab firstline treatment patients metastatic unresectable recurrent head neck squamous cell carcinoma pembrolizumab approved use combination platinum fluorouracil fu patients single agent patients whose tumors express combined positive score cps determined fda also expanded intended use ihc pharmdx kit include use companion diagnostic device selecting patients hnscc treatment pembrolizumab single july us fda approved pembrolizumab patients recurrent locally advanced metastatic squamous cell carcinoma esophagus escc whose tumors express combined positive score cps determined fdaapproved test disease progression one prior lines systemic fda also approved new use ihc pharmdx kit companion diagnostic device selecting patients june us fda approved pembrolizumab monotherapy treatment adults children unresectable metastatic tumor mutational burdenhigh tmbh mutationsmegabase mutmb solid tumors determined fdaapproved test progressed following prior treatment satisfactory alternative treatment march accelerated approval indication us treatment people metastatic small cell lung cancer sclc pembrolizumab priced per year launched late added cancer drugs fund list english nhs november confidential deal manufacturer merck reported results cancer types much attention given early results head neck may pembrolizumab phase ib clinical trials triplenegative breast cancer tnbc gastric cancer urothelial cancer head neck cancer trial phase ii trial tnbc asco june merck reported clinical development program directed around cancers running clinical trials around combination treatments four registrationenabling studies results phase iii clinical trial triplenegative breast cancer reported annals oncology october results phase ii clinical trial merkelcell carcinoma reported new england journal medicine june results clinical trial people untreatable metastases arising various solid tumors published science clinical phase iii trial combination epacadostat indoleamine inhibitor treat melanoma completed researchers reported results fiveyear followup january neoleukin therapeutics announced collaboration merck combination clinical trial mercks pembrolizumab neoleukins de novo protein undergoing phase clinical trial patients advanced relapsed refractory solid march merck reported results phase iii clinical trial patients stage recurrent endometrial merck moderna tested modernas drug candidate cancer vaccine alongside pembrolizumab treatment skin pancreatic cancers went win breakthrough status immune activation dostarlimab ibalizumab httpsenwikipediaorgwikipembrolizumab